XNCR - Vir Biotech nabs $50M BARDA funding to discover antibody therapies
2023-10-03 09:50:40 ET
More on Vir, Xencor, etc.
- Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity
- Vir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript
- Vir stock hits new 52-week low in wake of BofA downgrade
- Vir Biotech plunges as mid-stage study for flu candidate fails
For further details see:
Vir Biotech nabs $50M BARDA funding to discover antibody therapies